Solid Dispersion of 3β-Hydroxyurs-12-en-28-oic Acid via Low-Temperature Melt Extrusion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The limited solubility and bioavailability of 3β-hydroxyurs-12-en-28-oic acid, a naturally-derived lipophilic pentacyclic triterpene, hinder its clinical applications due to rapid metabolism and poor absorption, and existing methods like hot melt extrusion face challenges such as thermal degradation and recrystallization, limiting scalability and reproducibility.
Innovation Solution
A solid dispersion of 3β-hydroxyurs-12-en-28-oic acid is prepared using a water-soluble polymer with a glass transition temperature lower than 284°C, processed through melt extrusion at controlled temperatures to convert the crystalline structure to an amorphous form, enhancing solubility and bioavailability without the need for solvents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hot melt extrusion is used to improve solubility and bioavailability, then the amorphous form is achieved, but thermal degradation occurs at high process temperature
Solution Approach 1:
The patent changes the temperature parameter from conventional high-temperature HME (above drug melting point) to low-temperature melt extrusion (below drug melting point but above polymer Tg). This parameter change allows the active ingredient to remain in crystalline form during processing, avoiding thermal degradation while still achieving solubility enhancement through the amorphous polymer matrix.
Solution Approach 2:
The patent introduces a water-soluble polymer as an intermediary carrier that dissolves at processing temperatures below the drug's melting point. This polymer mediator enables the extrusion process to occur at lower temperatures, protecting the thermally sensitive active ingredient from degradation while still achieving the desired amorphous dispersion state.
2Reliability
If hot melt extrusion is used to maintain amorphous state, then solubility is improved, but recrystallization occurs during storage
Solution Approach 1:
The patent changes the processing temperature parameter to remain below the drug's melting point, preventing the drug from entering a fully molten state that would facilitate recrystallization. The low-temperature process creates a more stable amorphous dispersion that resists recrystallization during storage.
Solution Approach 2:
The patent creates a composite material system where the active ingredient is dispersed within a water-soluble polymer matrix. This composite structure provides physical stabilization to the amorphous state, preventing drug molecules from reorganizing into crystalline form during storage while maintaining enhanced solubility.
3Manufacturing precision
If conventional HME is used for processing, then molecular level mixing is achieved, but difficulty to obtain reproducible physicochemical properties limits scalability
Solution Approach 1:
The patent establishes specific parameter ranges for low-temperature melt extrusion (temperature below drug melting point but above polymer Tg, specific residence times, controlled feed rates) that ensure reproducible results. These defined parameters make the process scalable and manufacturable while maintaining consistent amorphous dispersion quality.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves a significant four-fold improvement in bioavailability, maintains the amorphous form for extended storage, and ensures thermal stability and reproducible physicochemical properties, overcoming previous limitations in scalability and stability.
Implementation Method 1
A solid dispersion of 3β-hydroxyurs-12-en-28-oic acid is prepared using a water-soluble polymer with a glass transition temperature lower than 284°C, processed through melt extrusion at controlled temperatures to convert the crystalline structure to an amorphous form
Implementation Method 2
processed through melt extrusion at controlled temperatures to convert the crystalline structure to an amorphous form
Data Source
AI summary
The present invention relates to a solid dispersion with improved bioavailability of an insoluble medicament, particularly a solid dispersion of the insoluble medicament, 3β-hydroxyurs-12-en-28-oic acid, and a preparation method thereof.